8-KOther EventsExhibits & Filings

NXP Semiconductors N.V. 8-K Report, Corporate Update (Aug 27, 2020)

Filed August 27, 2020For Securities:NXPI

Summary

NXP Semiconductors N.V. (NXPI) has announced a regular quarterly interim dividend payment for the third quarter of 2020. The Board of Directors approved a dividend of $0.375 per ordinary share, demonstrating a commitment to returning capital to shareholders. This action signals continued confidence in the company's financial stability and operational performance despite the broader economic uncertainties of 2020. Investors can expect this dividend to be paid on October 5, 2020, with a record date of September 15, 2020. This timely dividend payout is a positive signal for income-focused investors and reflects NXP's ability to generate consistent cash flows. The announcement, made via a press release, provides transparency and allows shareholders to plan accordingly.

Key Highlights

  • 1NXP Semiconductors N.V. (NXPI) announced an interim dividend for Q3 2020.
  • 2The approved dividend amount is $0.375 per ordinary share.
  • 3The dividend payment date is scheduled for October 5, 2020.
  • 4Shareholders of record as of September 15, 2020, will be eligible to receive the dividend.
  • 5This filing (8-K) primarily serves to officially announce the dividend approval and payment details.
  • 6The announcement reinforces NXP's commitment to shareholder returns.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce the Board of Directors' approval of an interim dividend payment for the third quarter of 2020 and to provide the specific details regarding the payment date and record date.

The dividend amount is $0.375 per ordinary share. It will be paid on October 5, 2020.

Shareholders who are of record as of September 15, 2020, will be eligible to receive the dividend payment.

The approval and planned payment of a regular quarterly dividend generally indicate that the company's Board of Directors is confident in NXP's current financial health and its ability to generate sufficient cash flow to support shareholder returns.